论文部分内容阅读
将205例尘肺观察对象按是否接受抗矽治疗分为两组,以观察抗矽治疗在抑制和稳定病变发展中的作用和效果。结果显示,肺通气功能指标(FVC%、FEV1.0%、FEV1.0/FVC%和MVV%)、肺纤维化检测指标[血液唾液酸值(SA)、血清铜蓝蛋白(CP)],治疗组2010年与2009年比较差异无统计学意义(P>0.05),未治疗组2010年与2009年比较各指标明显降低,差异有统计学意义(P<0.05);高仟伏胸片1级密集度小阴影形态、分布范围及诊断,未治疗组较治疗组高,差异有统计学意义(P<0.05)。提示给予尘肺观察对象适当的抗矽治疗,可延缓部分尘肺观察对象发展为壹期尘肺,进而减少尘肺病的发生。
205 cases of pneumoconiosis were divided into two groups according to whether they received anti-silicon treatment or not, so as to observe the effect and effect of anti-silicon treatment in inhibiting and stabilizing the development of the disease. The results showed that the indexes of pulmonary ventilation (FVC%, FEV1.0%, FEV1.0 / FVC% and MVV%), indicators of pulmonary fibrosis [blood sialic acid (SA) and ceruloplasmin (CP) There was no significant difference between the treatment group in 2010 and 2009 (P> 0.05), the index of the untreated group in 2010 and 2009 was significantly lower, the difference was statistically significant (P <0.05) Grade-intensive small shadow shape, distribution and diagnosis, no treatment group than the treatment group, the difference was statistically significant (P <0.05). Prompted to give appropriate observation of pneumoconiosis anti-silicon treatment, can delay the development of part of the object of pneumoconiosis developed pneumoconiosis, thereby reducing the incidence of pneumoconiosis.